Researchers have shown that inhalable gene therapy can completely reverse pulmonary arterial hypertension in rat models and reduce expression of SERCA2a, an enzyme critical for calcium pumping. This approach may offer a promising therapeutic intervention for PAH patients.
A gene mutation disrupts immune cell activity, causing liver attacks in autoimmune hepatitis. Researchers create model to study treatment targets and therapies.
Researchers at Mount Sinai identified a critical protein called VP35 that deactivates the innate immune system, allowing Ebola viruses to spread. Overexpressing a cellular protein called PACT inhibited viral replication, providing a potential target for new treatments.
Dr. Valentin Fuster received the 2013 SCCT Arthur S. Agatston Cardiovascular Disease Prevention Award for his groundbreaking work on atherosclerosis development and prevention of coronary artery disease. The award honors Dr. Fuster's pioneering efforts in uncovering the molecular and cellular bases of atherosclerosis.
Researchers have identified a new chemical compound, CYM51010, that targets the opioid receptor complex and shows promise as an alternative to morphine. The compound is potent and less likely to result in tolerance and negative side effects.
Dr. Partho Sengupta presented the first-ever hologram presentation at the ASE's 2013 24th Annual Scientific Sessions, utilizing 3D digital images and expert interview recordings to analyze cardiovascular system structure, function, and flow patterns. This innovative presentation format was made possible through collaborative efforts of...
The Fondation Leducq has awarded a $6 million grant to a new global research network focused on cardiac regeneration. The network, which includes researchers from the Cardiovascular Research Center at Mount Sinai, aims to identify cellular and molecular targets for advancing cardiac regenerative therapeutics.
Researchers found that a single dose of Ritalin improved brain function in cocaine-addicted individuals, strengthening connections between regions involved in regulating emotions and behaviors. The study suggests potential as an add-on treatment for addiction to cocaine and other stimulants.
Mount Sinai researchers discover that diabetics using glucose meters at appointments have improved disease control. A study found that patients with controlled diabetes had a lower Hemoglobin A1c level compared to those without monitored glucose levels.
Researchers at Mount Sinai have made a breakthrough in programming blood-forming stem cells, which could lead to the development of patient-specific blood products. The study uses mouse fibroblast cells and identifies a combination of four genetic factors that can generate blood vessel precursor cells with hematopoietic cells.
Researchers at The Mount Sinai Medical Center found that commonly prescribed medications can either block or enhance beta-amyloid accumulation in the brain. Treatment with certain drugs has been shown to significantly reduce amyloid plaques and neurodegeneration in mice.
Researchers from the Seaver Autism Center at Mount Sinai identified common clinical symptoms of Phelan-McDermid Syndrome, including severe to profound intellectual disability, seizures, and low muscle tone. The study provides important guidance for developing a standardized assessment methodology for this disorder.
Researchers at Mount Sinai have discovered a novel liver progenitor cell that can be differentiated from human embryonic stem cells and produce mature liver cells. This breakthrough discovery has the potential to revolutionize the treatment of liver disease, potentially overcoming the organ shortage issue.
A pioneering study demonstrates the benefit of MRI in identifying mental illnesses such as bipolar disorder. The advanced imaging technique was able to correctly distinguish patients from healthy individuals with a high degree of accuracy, promising a new approach to diagnosis.
Mount Sinai researchers identified genetic markers for survival in melanoma patients and found high readmission rates after cancer surgery in non-teaching hospitals and among black patients. They also discovered low prevalence of spousal HPV infection, reassuring long-term partners that their risk is very low.
Two genetic mutations, PDGFRB and NOTCH3, have been identified as potential therapeutic targets for infantile myofibromatosis (IM), a rare and debilitating disorder. Current treatment options involve repeated surgical removal of tumors, which can be invasive and disfiguring.
Researchers found ketamine to be effective in treating treatment-resistant depression within 24 hours, with a response rate of 63.8% compared to 28% in the placebo group. The antidepressant benefits were durable after seven days, making ketamine a promising new treatment option for patients with severe and refractory forms of depression.
A study found that children living near toxic waste sites in lower and middle income countries have high blood lead levels, resulting in a loss of IQ points and higher incidence of mental retardation. The researchers estimated that 6 out of every 1,000 children could experience mild mental retardation.
A study by a Mount Sinai researcher found that toxic waste sites with high levels of lead and chromium cause a significant number of 'healthy years of life lost' among individuals living near the sites. The study calculated 828,722 lost years of full health due to disease, disability, or early death.
Researchers at Mount Sinai identified new targets for abnormal cell division, finding that blocking CDK7 can inhibit the activity of other critical enzymes CDK4 and CDK6. This discovery suggests turning off these enzymes may be an effective therapeutic target for preventing cancer cell proliferation.
Researchers identified a network of genes involved in inflammatory response driving Late Onset Alzheimer's Disease (LOAD), providing new understanding of key pathways and genes. The study suggests targeting the TREM2-TYROBP pathway as potential therapies for LOAD.
Researchers at Mount Sinai identify 14 genetic targets associated with heart rate, which could lead to new drugs for treating cardiovascular disease. The study's findings also shed light on the genetic regulation of heartbeats and cardiac conduction disorders.
Researchers at Mount Sinai have identified a soy-based compound, genistein, that can inhibit tumor cell growth and block Wnt signaling hyperactivity in colorectal cancer. Genistein has shown promise as an adjunctive treatment for metastatic colorectal cancer when used in combination with chemotherapy.
A recent review article highlights the need for preventive measures, genetic risk factors, and new diagnostic tools to identify the effects of traumatic brain injury (TBI) in athletes and soldiers. Researchers propose large-scale trials and genome-wide association studies to characterize CTE and develop prevention strategies.
Studies found that individuals with dementia and TBI may have distinct clinical characteristics, such as higher fluency and verbal memory scores. Additionally, elderly patients with TBI are at higher risk of premature death due to underlying health conditions or complications after injury.
Researchers at Mount Sinai Hospital are collaborating with the New York Stem Cell Foundation to use stem cells to gain a better understanding of Alzheimer's disease. The project aims to identify causes and cures for the common form of AD, using reprogrammed skin cells into brain cells.
Researchers have developed nanomedicines that home specifically to damaged tissue to repair it, preventing tissue damage in inflammatory conditions. These tiny, targeted drug particles have the potential to treat chronic diseases without side effects.
Researchers at Mount Sinai are studying spasmodic dysphonia, a neurological disorder characterized by vocal cord spasms. The team aims to identify new drug targets and diagnostic biomarkers using advanced neuroimaging methodologies.
A large-scale trial by The Mount Sinai Medical Center found that combination therapy did not improve clinical benefits over single drug treatment in multiple sclerosis patients, but reduced the development of new lesions. Combination therapy with Glatiramer Acetate and Interferon Beta-1a showed a reduction in MRI lesion accumulation.
A team of researchers found that a specific histone variant, macroH2A, prevents normal cells from being reprogrammed into cells resembling stem cells. This discovery has broad implications for how cells change during both normal and disease development.
A study published in Health Affairs found that Medicare patients who enrolled in hospice received better care at a significantly lower cost to the government. The study, led by researchers at Mount Sinai, showed annual savings of $2.4 million to $6.4 million for the government.
A new study published in Science Translational Medicine has found a strong link between binge drinking and the development of insulin resistance, which can lead to Type 2 diabetes. The research suggests that alcohol disrupts insulin-receptor signaling, causing inflammation in the brain and increasing the risk of metabolic disorders.
Researchers at Mount Sinai have discovered that the flu virus can essentially tell time, with a clock that dictates when it multiplies, infects cells, and spreads. This finding provides a novel design platform for the flu vaccine and could lead to new antiviral drugs that target the virus's internal clock.
Mount Sinai researchers have developed a playbook for treating fibrotic diseases, which are responsible for 45% of all deaths in the industrialized world. They've identified promising experimental drugs and biomarkers that will facilitate testing of new treatments.
A recent Mount Sinai survey reveals that nearly 1 in 3 children with food allergies are bullied, leading to increased stress levels and lower quality of life. The study highlights the importance of parents, school personnel, and physicians being aware of bullying in this population.
Researchers have identified numerous new genes associated with autism spectrum disorder using high-throughput sequencing technology. This discovery confirms that the genetic origins of autism are complex and may involve hundreds of mutations.
Pomalidomide, a new immunomodulatory drug, demonstrates significant increases in progression-free survival and overall survival for patients with relapsed and treatment-resistant multiple myeloma. The study found improved outcomes in both younger and older patients, offering a promising new option to extend survival.
Researchers found point-of-care ultrasound to be highly specific (97%) and sensitive (92%) for diagnosing pneumonia, outperforming the traditional method of auscultation by stethoscope. Ultrasound can also detect small pneumonias that a chest x-ray may miss, making it a valuable tool in pediatric care.
A survey of US hospices found that restrictive policies limit access to hospice care for patients requiring costly treatments. Reforming Medicare reimbursement rates and eligibility requirements is necessary to support patients and their providers.
A study published in Nature Neuroscience reveals that social isolation can reduce myelin production in mice, affecting the formation of new oligodendrocytes and leading to behavioral changes. Reintroduction into a social group reverses these effects, suggesting environmental factors play a crucial role in maintaining healthy nerve cells.
Researchers identified hundreds of regions in the human genome with unique chromatin structures that control cognitive behavior and expression. These findings provide new insights into diseases like Alzheimer's and autism.
Researchers at The Mount Sinai School of Medicine presented a study demonstrating IRX4204's ability to alleviate cognitive decline in animal models of Alzheimer's disease. The compound also prevents neuropathological features associated with abnormal tau processing, a common feature of Parkinson's disease with dementia.
Overeating can cause a malfunction in brain insulin signaling, leading to increased fatty acid levels, inflammation, and worsened insulin resistance. The study suggests that the brain's response plays a crucial role in developing type 2 diabetes, making it a potential target for improving insulin function.
Researchers have discovered potential new targets for treating depression by modulating dopamine cells and the innate immune system in mice. Increasing activity of dopamine neurons produced depressed behavior, while inhibiting them eased symptoms.
A six-gene signature has been identified that can predict survival in men with aggressive prostate cancer. The test uses blood samples and shows promise for determining the course of action for patients, clinical trial eligibility, and targeted studies.
Researchers at Mount Sinai School of Medicine have shown that large doses of vitamin C can stimulate bone formation and prevent bone loss in animal models. The study suggests that vitamin C may be a promising therapeutic agent for treating osteoporosis, particularly in developing nations where treatment options are limited.
Researchers found that a protein called BDNF is inhibited in opioid addiction, unlike cocaine where it's enhanced. The study identified two genes, sox11 and gadd45g, which mediated the brain's response to morphine, preventing reward and addiction.
A study has identified 12 genetic markers associated with erectile dysfunction in prostate cancer patients treated with radiation. The findings may help clinicians predict complications and develop therapies to alleviate side effects.
Researchers at Mount Sinai identified reliable predictors of pain in inpatients, enabling interdisciplinary teams to develop targeted intervention plans. These plans resulted in decreased pain levels and increased patient satisfaction across various departments, with reported pain levels decreasing by 3.6% per quarter.
Researchers Stuart Aaronson and Ross Cagan received a $351,713 grant from the National Cancer Institute to investigate signaling pathways responsible for Wnt oncogene addiction. They aim to discover potent drugs that can disrupt this addiction in tumor cells, increasing the efficacy of therapy for Wnt-activated human cancers.